Roche turned to real world evidence (RWE) to understand how a subgroup of patients with an anaplastic lymphoma kinase translocation (ALK) who were diagnosed with non-small cell lung cancer (NSCLC) responded to the drug alectinib. The use of RWE sped up research into the drug and led to regulatory approval. A follow-up study utilized quantitative bias analysis to understand how confounding data could impact findings.
“The ability to quantify bias present in RWE has value and utility in fast, accurate, safe, and effective clinical research. In the future, using this technique will make it possible to see how RWE studies could become a viable substitute for some interventional research.” Read more here.
(Source: Miruna Sasu, COTA, 10/21/21)